Translational Sciences

Translational Sciences invests in and supports the development and commercialization of cutting-edge diagnostics and therapeutics. It is one of the two focus areas at UPMC Enterprises.

Investing in the Future of Health Care

The Translational Sciences team combines scientific, clinical, and investment expertise to optimize the commercialization path for products and solutions addressing diseases with high unmet medical need. Our internal focus is to support the commercialization of cutting-edge research by launching early-stage companies. We are also looking for opportunities to invest in external companies at all stages that are developing innovative products to improve health care.

Supporting UPMC’s Immunotherapy Efforts

A top priority of Translational Sciences is to become a world leader in delivering new models of care to harness the human immune system to treat disease. UPMC committed $200 million to the Immune Transplant and Therapy Center (ITTC) in 2017 for investment in the areas of: cancer immunotherapy, transplantation, aging, and chronic diseases.

The team at UPMC Enterprises supports this immunotherapy effort by commercializing novel diagnostics and therapeutics in a select number of focus areas.

Combining VC Rigor with Research Expertise

We take a disciplined approach to conducting diligence, forming new companies, and investing in existing entities.

Our team includes seasoned individuals with several decades of venture capital experience, who have invested in life science companies that developed and commercialized products that led to successful exits. They are complemented by clinical, scientific, and operational advisors.

Importantly, we have access to research expertise at the University of Pittsburgh, which has been awarded more than $528 million in NIH funding in 2018. We also utilize the clinical acumen of UPMC physicians, and payer perspectives from the UPMC Health Plan. These resources allow us to monitor emerging trends in health care and to identify, support, and commercialize scientific breakthroughs that translate into meaningful improvements in medical care.

Expanding Our Scope

To enhance our commercialization efforts, we expanded our scope in 2018 to encompass areas beyond ITTC’s charter, including therapeutics, diagnostics, and devices. Our mission is to work with scientists and clinicians at UPMC to create successful startup companies, and to invest alongside top investors in external companies that complement our strategic focus.

In January 2020, we announced a commitment to invest $1 billion by 2024 in life sciences companies at all stages. 

Investment Approach

Backed by the clinical and financial strength of UPMC, we have the flexibility to invest in a broad range of opportunities, whether generated at the University of Pittsburgh or externally through a syndicate.

We work closely with researchers and scientific founders to expedite commercialization of their projects, and we are actively seeking partnerships with external investors to complement our internal efforts.

We can tailor the size of an investment to the situation and are looking for opportunities that fall within our current strategic priorities.

Current Investment Themes

The Translational Sciences team focuses our commercialization efforts in four distinct areas:

Cancer Immunotherapy

Immunotherapy is a new wave of cancer therapy that uses the individual's own immune system to fight cancer. We’re finding new ways to stimulate and harness the immune system to work harder and smarter for cures.

Transplantation

UPMC is one of the most experienced organ and bone marrow transplant centers in in the world. We’re now discovering innovative ways to help improve the lifespan of the transplanted organ with new trials, techniques, and therapies.

Aging & Chronic Diseases

As the aging population grows, it is imperative that we develop new therapies and treatments to help us live a longer, healthier life. We also want to address chronic diseases such as diabetes, heart disease, and neurological and autoimmune disorders that can often be controlled but not cured.

Enabling Technologies

Translating advances in research into improved medical care is facilitated by new technologies that make it possible to detect disease earlier, to understand underlying disease processes better and to develop improved treatments. We are excited about companies that develop these technologies and/or incorporate them in their research and discovery efforts.

  • Role:
  • All
  • leadership
  • advisors
  • team
Alex Anetakis, MD, MBA
Alex Anetakis, MD, MBA

Senior Advisor

Read Bio

Senior Advisor

Alex Anetakis, MD, MBA, joined UPMC Enterprises in March 2018, and serves as a physician advisor to the Translational Sciences team at UPMC Enterprises, with focus on ophthalmology-related investments. Dr. Anetakis is a vitreo-retinal surgeon who completed his training in 2006 and was initially in private practice in South Carolina for two years prior to joining UPMC’s Department of Ophthalmology in 2008. He has special interests in age-related macular degeneration, diabetic retinopathy, and diseases of the vitreo-retinal interface. Dr. Anetakis graduated from Northeastern Ohio, College of Medicine and completed his MBA at the Tepper School of Business at Carnegie Mellon University.

Rosheema Bala
Rosheema Bala, MS
Rosheema Bala, MS

Analyst

Read Bio

Analyst

Rosheema Bala is an analyst with Translational Sciences at UPMC Enterprises. Rosheema joined UPMC Enterprises in 2021 to help support internal and external investment portfolios through investment diligence, operational support, and business development.

Before joining UPMC Enterprises, Rosheema interned with the Advanced Innovation group at Philips where she worked on providing unique market insights to identify new product opportunities in the sleep and respiratory care space. Rosheema brings a broad range of experience working with both startups and corporate startup groups in the healthcare industry. She has identified and charted business plans to advance several high-impact projects for them.

Rosheema graduated from Carnegie Mellon University with an M.S. in Biomedical Engineering and an M.S. in Engineering and Technology Innovation Management.

Jamie Bauersmith
Jamie Bauersmith, JD, MS
Jamie Bauersmith, JD, MS

Vice President, Translational Sciences

Read Bio

Vice President, Translational Sciences

Jamie is an experienced healthcare executive with over 20 years of experience across a variety of healthcare segments. He joined UPMC Enterprises in August of 2021 as Vice President of Translational Sciences. Before joining Enterprises, Jamie was the Chief Strategic Officer and General Counsel of ByHeart, Inc., an infant formula company, where he led the company’s FDA strategy, managed all of their legal affairs and led the acquisition and set-up of the company’s manufacturing facility. Prior to his role at ByHeart, Jamie worked in the pharmaceutical sector for over 15 years where he held a variety of leadership positions at Fresenius Kabi, where he was the SVP overseeing the company’s portfolio and marketing strategy unit, and Amneal Pharmaceuticals where he oversaw the corporate development and procurement groups and was part of the executive management team.

Before his tenure at Fresenius and Amneal, Jamie spent 10 years practicing law, first as an attorney in New York with Haug Partners and then as in-house counsel at Teva Pharmaceuticals where he managed the company’s Hatch Waxman Patent litigations. He earned a B.S. from the University of Notre Dame, a J.D. from the Pennsylvania State University School of Law, and an M.S. of Bioscience and Biotechnology from Drexel University. He is a registered U.S. Patent Attorney and maintains an active Pennsylvania law license.

At Enterprises, Jamie focuses his time on identifying, analyzing and structuring investment opportunities that address unmet therapeutic need and align with UPMC’s vision of bringing life changing medicine to patients.

Annette Bianchi
Annette Bianchi

Senior Advisor

Read Bio

Senior Advisor

Annette has over 35 years of venture capital investment experience with over 32 years as a General Partner or Managing Director.

Annette was a seed investor and played a key role in the formation of Cephalon (CEPH) which was acquired by Teva Pharmaceuticals for $6.8 billion. She was also a seed investor in CellPro (CPRO), ProDuct (acquired by Cytyc), Vivant (acquired by Tyco), and InnerDyne (merged with CardioPulmonics – acquired by Covidien).

She has invested in numerous other companies including Anthera (ANTH), Conceptus (CPTS-acquired by Bayer for $1.1 billion), Coulter (acquired by Corixa for $900M), Ligand (LGND), Oacis (OCIS – acquired by SAIC), Orquest (acquired by DePuy), Phase Forward (PFWD – acquired by Oracle), Targegen/Impact (acquired by Sanofi-Aventis for $560M/spun out as Impact BioMedicines and then acquired by Celgene for $7 billion), and Telik (TELK).

Annette began her venture capital career in 1985 as an Associate and later a General Partner at Burr, Egan, Deleage & Company. In 1992, she joined Weiss, Peck & Greer Venture Partners as a General Partner and subsequently became a Managing Director at Pacific Venture Group in 1999. In 2004, she became a Managing Director at VantagePoint Capital Partners until she founded Red Tailed Hawk Venture Partners.

Annette is a graduate of the University of Pennsylvania (BSE and MSE) in Biomedical Engineering and The Wharton School (MBA).

Jeanne Cunicelli, MBA
Jeanne Cunicelli, MBA

President, UPMC Enterprises

Read Bio

President, UPMC Enterprises

Jeanne Cunicelli, a veteran venture capitalist in the life sciences industry, became president of UPMC Enterprises in January 2021. Cunicelli was a managing director at Bay City Capital in San Francisco before joining UPMC in 2017 to lead UPMC Enterprises’ Translational Sciences focus area.

As president of UPMC Enterprises, Cunicelli is leading UPMC’s efforts to commercialize its managerial and health care expertise. With a focus on improving the quality, efficiency and patient experience at UPMC, the division and its partners will then take those solutions to the broader health care market through its two focus areas, Translational Sciences and Digital Solutions.

Under Cunicelli’s leadership, the Translational Sciences team has grown to more than 20 scientific and investment professionals working to accelerate the transfer of scientific discoveries into life-changing medicines, diagnostics and devices. Based on ground-breaking research from the University of Pittsburgh and other global innovators, the team will deploy $1 billion in life sciences investments by 2024. Through its Digital Solutions group, UPMC Enterprises has started and invested in a portfolio of companies that leverages UPMC’s scale and health care insights to provide clinicians, payers and consumers with engaging technology that improves the quality and cost effectiveness of health care.

Cunicelli is a member of the Board of Trustees of Carnegie Mellon University. She received an M.B.A. from the University of San Francisco and a bachelor’s degree in cognitive psychology from Carnegie Mellon University.

Clapton Dias, BPharm, PhD
Clapton Dias, BPharm, PhD

Vice President, Head of Portfolio Development

Read Bio

Vice President, Head of Portfolio Development

Clapton Dias BPharm, PhD, currently serves as Vice President, Head of Portfolio Development, driving research ideas at UPMC Enterprises to life changing medicines. He is a member of the Senior Investment Committee focused on external investments for UMPC, Translational Sciences.

Clapton has spent almost two decades in pharmaceutical/ biotechnology companies as a Clinical Pharmacology and Program/Portfolio Leader. Previously, he was Vice President, at BioMarin, a rare disease company overseeing over 15 programs and a team of strategy leaders for programs in the translational, clinical development & marketed phases. These programs spanned small molecules, peptides & innovative platforms including AAV gene therapies. Clapton served as chair of the product strategy governance committee enabling decision making and led the revamp of team structure to bring efficiencies to planning & execution. He was also Head of Clinical Pharmacology (nonclinical Pk/PD, DMPK and clinical) at BioMarin where he and his team successfully obtained approvals for Palynziq, a pegylated enzyme treatment for PKU and Brineura for Batten’s disease. Prior to BioMarin, Clapton worked at Janssen in the diabetes therapeutic area contributing to lifecycle planning for Invokana (SGLT2 inhibitor). He was Early Development and Clinical Pharmacology Leader at Amgen for several programs in the cardiovascular, inflammation and neuroscience therapeutic areas. Notably, Clapton was the early development leader for Repatha, a PCSK9 mAb for Hypercholesterolemia from pre-IND to approval. Clapton also helped build device capabilities at Amgen for large molecule SC delivery and was the clinical pharmacology lead for the approved on-body SC infusion devices for Repatha and Neulasta. Prior to Amgen, Clapton was a member of the development team for Eliquis, a factor Xa inhibitor at Bristol Myers Squibb where he designed and directed several clinical pharmacology studies that informed dosing and labeling.

Clapton received his Bachelor’s degree in Pharmacy from University of Mumbai, India and an interdisciplinary PhD in Pharmaceutical Sciences from the University of Missouri, Kansas City, USA. Clapton is passionate about bringing impactful solutions to better patient lives and healthcare.

Kathy Griffin
Kathy Griffin

Executive Assistant

Read Bio

Executive Assistant

Kathy works with the Translational Sciences Core Team as an Executive Assistant and provides administrative and logistical support for the portfolio companies. She has been working with UPMC since 2011, before which she was working for a Fortune 500 company for 18 years.

Jessica Furnier, MHA
Jessica Furnier, MHA

Director of Operations

Read Bio

Director of Operations

Jessica Furnier, MHA, is Director of Operations, Translational Sciences at UPMC Enterprises. While Jessica officially joined Enterprises in August 2020, she has been working with the team since its inception.

Jessica brings over ten years with UPMC in varying roles from lab technician (immunogenetics) to project manager to now overseeing multiple departments. In her current role, she is responsible for all of the “behind the scenes” functions that enable and support the overarching investment strategy and works closely with internal portfolio projects.

Jessica also serves as Director of the Chief Medical and Scientific Office at UPMC, which provides funding and project management support for system wide initiatives.

Jessica earned a BS in Biology from Duquesne University and an MHA from the University of Pittsburgh.

Bill Gerber, MD
Bill Gerber, MD

Senior Advisor

Read Bio

Senior Advisor

Bill Gerber, MD, is an Advisor to the Translational Sciences program at UPMC Enterprises. Dr. Gerber received his medical training at the University of California, San Francisco, and completed a Family Practice Residency at San Francisco General Hospital. After practicing family and emergency medicine, he pursued a career in the biotechnology industry, holding senior positions at Cetus, Chiron, Onyx Pharmaceuticals, and Epoch Biosciences. Dr. Gerber then joined Bay City Capital, a venture capital firm investing in life science companies, as a venture partner and served on multiple boards over the next ten years. He currently serves as a consultant to the biotechnology industry.

rob hartman phd
Rob Hartman, PhD
Rob Hartman, PhD

Director

Read Bio

Director

Rob Hartman, PhD, has over 10 years of healthcare and commercialization experience. He is currently a Director of Translational Science at UPMC Enterprises, where he leads strategy and operational support for portfolio companies, supports investment strategy and diligence, and serves as a connector of teams and opportunities spanning life sciences and digital health technology. Before moving to Translational Science, Dr. Hartman led the Pittsburgh Health Data Alliance, a program that enables UPMC to support and commercialize potentially disruptive innovation in healthcare with multi-million-dollar annual investments in health-related, data-intensive, local, academic research. Prior to working with UPMC, he was an innovation and commercialization consultant within the University of Pittsburgh where he received his Bachelor’s, Master’s, and Doctorate degrees in bioengineering.

Matthias Kleinz, DVM, PhD
Matthias Kleinz, DVM, PhD

Senior Vice President, Translational Sciences

Read Bio

Senior Vice President, Translational Sciences

Matthias Kleinz, DVM, PhD, is Senior Vice President, Translational Programs at UPMC Enterprises. Matthias joined UPMC Enterprises in July 2017 to help the ITTC invest and commercialize innovative translational science by defining the true potential of new life science technologies, exploring optimal business models and strategies, and helping to form companies with a clear path to success. Matthias sits on the board of UPMC Enterprises portfolio companies Generian and Cerevance and is the startup CEO of one of UPMC’s latest drug discovery startups. He is also a member of the executive committee for the UPMC Genome Center. Prior to UPMC Enterprises, Matthias spent nine years in management consulting at L.E.K. Consulting in its life sciences practice in Boston and London leading teams on over 70 strategic assignments for clients in the U.S., Europe, and Japan. Matthias completed his PhD in the Clinical Pharmacology Unit of the University of Cambridge (UK), working on early stage discovery of G-protein-coupled receptor targets for hypertension, heart disease, and metabolic syndrome and graduated from Justus Liebig University in Giessen (GER) with a doctorate in clinical veterinary medicine.

Adrian Lee, PhD
Adrian Lee, PhD

Senior Advisor

Read Bio

Senior Advisor

Adrian Lee, PhD, is a Professor of Pharmacology & Chemical Biology, and Professor of Human Genetics. He serves as Director of the Institute for Precision Medicine (IPM), a joint effort by UPMC and the University of Pittsburgh. Dr. Lee has a key role in shaping precision medicine research. An example is the successful implementation of clinical pharmacogenomics, and development of computational systems and architecture for sharing of clinical and genomic data both at the University of Pittsburgh and UPMC. Dr. Lee has published over 160 peer reviewed research articles. His laboratory is supported by funding from the Department of Defense, Susan G. Komen for the Cure, Breast Cancer Research Foundation, and other sources. Dr. Lee serves on numerous national peer-review committees, and is on the Editorial Boards of several journals. Dr. Lee received his PhD in Oncology and Cancer Biology from the University of Surrey.

Rob Lin, PhD, CFA
Rob Lin, PhD, CFA

Vice President

Read Bio

Vice President

Rob Lin, PhD, CFA, is Vice President of Translational Programs at UPMC Enterprises. Dr. Lin joined the ITTC team in October 2017 to help commercialize UPMC’s immunotherapy research. Before UPMC, Dr. Lin worked for the Bill & Melinda Gates Foundation, leading the finance and strategy activities for the Global Health Program. Dr. Lin earned a PhD in Genetics at Harvard University and then transitioned into business and corporate development at Millennium Pharmaceuticals (now Takeda Oncology).

JoAnn Lucibello
JoAnn Lucibello
JoAnn Lucibello

Project Administrator

Read Bio

Project Administrator

JoAnn works with the Translational Sciences Team as Project Coordinator to assist with planning, development, and execution of its commercialization efforts. She has extensive experience in the life sciences industry and has been with UPMC since 2017.

Anna Mamo, MBA, MS
Anna Mamo, MBA, MS

Director, Translational Sciences

Read Bio

Director, Translational Sciences

Anna Mamo has a broad background in the biological sciences and experience in business case development to support the UPMC Enterprises Translational Sciences team. Ms. Mamo’s early career focused on research, with time spent in academic labs focusing in genetics and immunology. She has previous experience with a Pittsburgh-based start-up company, Carmell Therapeutics, which developed regenerative bone and tendon therapies. After developing an interest in the business side of science, she went back to school for her MBA at the Katz Graduate School of Business. After graduating, Ms. Mamo worked on commercializing health care-related technologies that spun out of Pittsburgh universities. She spent time with the Coulter Foundation, Idea Foundry, and Highmark Health, in their innovation and strategic partnership departments. After helping to launch an enterprise-wide technology commercialization process (VITAL) at Highmark, she left for UPMC Health Plan, where she led a team developing business cases for consumer-facing digital technologies. Ms. Mamo graduated from Grove City College with a Bachelor’s degree in Biology and French and followed her undergraduate education with a Master’s degree in Microbiology and Infectious Disease from the Pitt Graduate School of Public Health.

Bruce Pitt, MD, PhD
Bruce Pitt, MD, PhD

Senior Advisor

Read Bio

Senior Advisor

Bruce Pitt, MD, PhD, is a physician advisor to Translational Sciences team at UPMC Enterprises. Dr. Pitt is now Professor of EOH, Pharmacology and Bioengineering at University of Pittsburgh Graduate School Public Health and School of Medicine. Prior to this, Dr. Pitt was Chairman of Environmental and Occupational Health, and he has been continuously funded from the NIH for almost 40 years for studies on the role of partially reduced oxygen and nitrogen species and metal ion homeostasis in pulmonary endothelium in acute lung injury and pulmonary hypertension. He was the recipient of an NIH MERIT award and Established Investigator from American Heart Association and has served on numerous review panels including chairing NIH Lung Biology Pathology, California Tobacco Related Disease Program and American Lung Association. He was Chair of Assemblies of Pulmonary Circulation and Molecular Respiratory Cell Biology (American Thoracic Society) and Respiratory Physiology (American Physiologic Society). He has been on scientific advisory board of iNO Therapeutics, Gilead Pharmaceuticals and Parker B Francis Foundation. Dr. Pitt received his BA from Brown University and PhD in environmental physiology from The Johns Hopkins University and M.D. at Yale University School of Medicine.

Joe Pohl
Joe Pohl, JD
Joe Pohl, JD

Executive in Residence

Read Bio

Executive in Residence

An experienced business attorney and executive leader, Joe joined UPMC Enterprises as an Executive in Residence in June 2021. Prior to joining Enterprises, Joe served as the CEO of PharmBlue LLC, a national specialty pharmacy company based in the Pittsburgh area, where he led a revitalization of the company, capped by a successful exit for the investors in a private equity transaction. He joined PharmBlue as its first General Counsel and a member of the Executive team.

Before his tenure at PharmBlue, Joe spent 19 years practicing law, primarily with Reed Smith LLP. He earned a B.A. from the University of Notre Dame, a J.D. from the University of Pittsburgh School of Law, and maintains an active Pennsylvania law license.

At Enterprises, Joe provides management and leadership support to the Translational Sciences and Digital Solutions teams on internal initiatives and external interests, including portfolio companies.

Hank Safferstein, PhD, JD, MBA
Hank Safferstein, PhD, JD, MBA

Senior Advisor

Read Bio

Senior Advisor

Hank Safferstein, PhD, JD, MBA, currently serves as a Senior Advisor, UPMC Enterprises and CEO, Generian, a UPMC portfolio company. He is Board Director of Ariel Precision Medicine. Previously, he was Senior Vice President of Cognition Therapeutics, a clinical stage, small molecule, Alzheimer’s disease company and Adjunct Professor at Carnegie Mellon University. He was Founder and CEO of Cognition Therapeutics and Complexa, Inc., a clinical stage biotechnology company focused on fibrosis and inflammation for orphan disease indications. Dr. Safferstein served as Vice President, Business Development, for Omrix Biopharmaceuticals, a commercial-stage company that develops and markets biosurgical and passive immunotherapy products (acquired by J&J) and was Vice President, Business Development for Acorda Therapeutics, a central nervous system drug development and marketing company. Prior to joining Acorda Therapeutics, Dr. Safferstein served in various business development and marketing positions with Bristol-Myers Squibb. From 1991-1997, he was Director, Technology Transfer at the National Heart, Lung and Blood Institute and Cooperative Venture Manager for the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Dr. Safferstein was an NIH Post-Doctoral Fellow and Fellow of the Multiple Sclerosis Society.

Dr. Safferstein received a BA in Biochemistry from Rutgers University, a PhD in Human Anatomy and Neurobiology from the University of Louisville, a JD from the American University, Washington College of Law and an MBA from Columbia University. He is an active member of the Maryland Bar.

Harinder Singh, PhD
Harinder Singh, PhD

Senior Advisor

Read Bio

Senior Advisor

Harinder Singh obtained his Ph.D. at Northwestern University mentored by Dr. Lawrence Dumas (1979-84) and was a Jane Coffin Childs Postdoctoral fellow at MIT mentored by Drs. Phillip Sharp and David Baltimore (1984-88). He was a member of the faculty of the University of Chicago from 1989-2009, becoming a Louis Block Professor of Molecular Genetics and Cell Biology and an Investigator of the Howard Hughes Medical Institute. In January 2019, Harinder accepted a position as the Director at the Center for Systems Immunology at the University of Pittsburgh. He previously served as Senior Director of Discovery Immunology and as a Staff Scientist at Genentech from 2009-2013. From 2013-2018, he was on the faculty of the Cincinnati Children’s Hospital Medical Center as Director of the Division of Immunobiology and the Center for Systems Immunology. He has served as an Editor of the Journal of Molecular and Cellular Biology and as a Chair of the Board of Scientific Counselors (Basic Research) of the National Cancer Institute.

He has had a longstanding interest in the analysis of transcription factors and gene regulatory networks that regulate the development and functioning of innate and adaptive cells of the immune system. His lab discovered that the Ets family member PU.1 is required for the development of multiple lineages of the innate and adaptive immune system and that graded levels of PU.1 are used to orchestrate innate versus adaptive immune cell fates. The Singh lab has been particularly interested in gene regulatory networks that orchestrate B cell fate specification, pre-B cell differentiation, B cell activation and plasma cell generation. Molecular biology and genomic approaches along with mathematical modeling have been used to assemble and analyze such networks. This conceptual and experimental framework is being extended to enable analysis of antigen-specific B as well as T cell responses in the context of vaccination, infection or autoimmune diseases in humans.

Christopher Stern, PhD
Christopher Stern, PhD

Senior Director

Read Bio

Senior Director

Christopher Stern, PhD is Senior Director, Translational Sciences at UPMC Enterprises. Chris joined UPMC Enterprises in February 2021 to help invest in innovative life science companies and to support the commercialization efforts of the internal portfolio. Prior to UPMC Enterprises, Chris was a Principal in L.E.K. Consulting’s Healthcare and Life Sciences practice supporting biopharma, diagnostic, and pharma service clients in the U.S., Europe, and Asia with key strategy, business development, and commercial issues. Chris completed a PhD in Neuroscience at the University of Minnesota working on neuronal stress peptide signaling pathway, and studied synchronous neural networks and epilepsy as a Postdoctoral Scholar at the Stanford University School of Medicine.

Peter Wipf, PhD
Peter Wipf, PhD

Senior Advisor

Read Bio

Senior Advisor

Peter Wipf, PhD, is the Distinguished University Professor of Chemistry and Professor of Pharmaceutical Sciences and Bioengineering at the University of Pittsburgh. He directs the Center for Chemical Methodologies and Library Development, and he is a member of the board of several companies, journals, and societies. Dr. Wipf is a Fellow of the American Chemical Society, the American Association for the Advancement of Science, and the Royal Society of Chemistry. His research contributions include the total synthesis of natural products, organometallic and heterocyclic chemistry, medicinal and computational chemistry. He has coauthored over 600 journal articles, books and patents.

Socrates Zacharias
Socrates Zacharias

Senior Director

Read Bio

Senior Director

Socrates Zacharias is a Senior Director, Translational Sciences at UPMC Enterprises. Socrates joined UPMC Enterprises in April 2020 to help invest in life science companies and to support the development efforts of the group’s internally-formed company portfolio. Coming from an investment banking background, Socrates previously worked at Leerink Partners (now SVB Leerink) where he focused on public and private capital raises for emerging biotech companies. Subsequent to Leerink, he worked at PNC Capital Markets advising companies on financing strategies and capital structures. Socrates graduated from Carnegie Mellon University with a B.S. in Biological Sciences and Psychology and an M.S. in Biotechnology and Management.

Posts from the Blog